24
Participants
Start Date
September 1, 2011
Primary Completion Date
September 12, 2013
Study Completion Date
September 12, 2013
AC220
Dose assigned at study entry. AC220 will be given orally once daily on days 7-28.
Cytarabine
"All patients receive 1000 mg/m2/day IV given every 12 hours on days 1 through 5. Additionally, AML patients and patients with ambiguous leukemia receive cytarabine intrathecally on day 1 of course 1 and 2. Dose defined by age:~* 20 mg for patients age \<1 yr~* 30 mg for patients age 1-1.99 years of age~* 50 mg for patients age 2-2.99 years of age~* 70 mg for patients \>3 years of age"
Etoposide
150 mg/m2/day IV on days 1 through 5.
Methotrexate
"IT methotrexate given intrathecally to patients with ALL on day 0 of course 1 and 2. Dose defined by age~* 6 mg for patients age \< 1yr~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age"
Johns Hopkins University, Baltimore
Levine Children's Hospital at Carolinas Medical Center, Charlotte
Children's Healthcare of Atlanta, Emory University, Atlanta
Children's Mercy Hospitals and Clinics, Kansas City
The Children's Hospital, University of Colorado, Aurora
Childrens Hospital Los Angeles, Los Angeles
Children's Hospital Central California, Madera
Oregon Health and Science University, Portland
Seattle Children's Hospital, Seattle
UCSF School of Medicine, San Francisco
Dana Farber, Boston
Collaborators (1)
Ambit Biosciences Corporation
INDUSTRY
Therapeutic Advances in Childhood Leukemia Consortium
OTHER